Shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) dropped 4.5% on Wednesday . The stock traded as low as $3.35 and last traded at $3.60. Approximately 159,929 shares changed hands during trading, an increase of 365% from the average daily volume of 34,393 shares. The stock had previously closed at $3.77.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of Phio Pharmaceuticals in a research note on Tuesday, May 14th.
Read Our Latest Research Report on PHIO
Phio Pharmaceuticals Trading Up 3.6 %
Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($4.23) earnings per share (EPS) for the quarter. Equities analysts forecast that Phio Pharmaceuticals Corp. will post -16.38 earnings per share for the current fiscal year.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.
Read More
- Five stocks we like better than Phio Pharmaceuticals
- How to Choose Top Rated Stocks
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Stock Dividend Cuts Happen Are You Ready?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Top Stocks Investing in 5G Technology
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.